Job title: CSO
Dr. Nancy Tawil, M. Eng, PhD, is the Vice President of Research, Human Health Division at Phagelux Inc, a platform company specializing in the use of bacteriophages and endolysins as a way of combating bacterial and multi-drug resistant infections. With over 15 years of research experience in the areas of bacterial infections, anti-infectives, bacteriophages, and the application of biodegradable polymers in the treatment of multi-drug resistant infections, Dr Tawil’s main focus is on the development of novel drug delivery systems. She has recently been granted patent rights to novel microencapsulation systems and is named inventor on multiple patent pending technologies. In addition to her role as Vice President of Research, Human Health Division at Phagelux Inc., Dr. Tawil currently holds the position of Associate Professor of Biomedical Engineering at École Polytechnique de Montréal. She holds a BSc. Physiology (McGill University), a M.Eng in Chemical Engineering and a PhD in Biomedical Engineering (École Polytechnique de Montréal). As an industry expert, Dr. Tawil, is committed to bridging the gap between science and technology to find innovative solutions to the growing challenges of a drug resistant world.
Question & Answer Session 9:40 am
day: Day Two
Delivery of Phage-Based Drugs, and Their Incorporation in Medical Devices 9:00 am
day: Day Two